BioAge Labs at UBS conference: pivots BGE-102 toward eye disease
At the UBS Global Biopharma Conference on November 16, 2026, BioAge Labs unveiled a revised strategy for its lead inflammation drug, BGE-102, and expanded its focus to obesity and aging biology. The company acknowledged a more challenging market for large cardiovascular outcomes trials following Novo Nordisk's failed ZEUS trial.
BioAge is shifting BGE-102's focus from cardiovascular outcomes towards ophthalmology, particularly diabetic macular edema. Phase I data revealed up to 98% suppression of IL-1β, 86% reduction in CRP, and tolerability similar to placebo, with confirmed penetration to the brain and retina. The company holds approximately $350 million in cash, which is expected to support its programs through 2029.
BioAge is advancing two APJ agonist programs, with an IND filing planned for late 2024. Despite a cautious stance on cardiovascular disease, the company remains optimistic about eye disease. BioAge's lead asset, BGE-102, is an oral NLRP3 inhibitor that targets upstream IL-1β and IL-18, which are associated with inflammation. The drug has demonstrated strong pharmacology and tolerability in multiple studies.
BioAge's QUELL-CV study is a Phase II dose-ranging trial in obese individuals with elevated CRP and cardiovascular risk, while the QUELL-DME program is a Phase II proof-of-concept trial for diabetic macular edema. The oral route of BGE-102 could potentially benefit patients by reducing the need for injections and enabling more convenient management of the disease.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.